The most commonly reported postoperative complications were lung infection, arrhythmia, and pneumothorax.<h4>Conclusion</h4>Neoadjuvant EGFR-TKI therapy provides a feasible treatment modality for patients with resectable or potentially resectable EGFR-mutant NSCLC, with satisfactory surgical outcomes and low toxicity. This evidence concerns the gene EGFR and pneumothorax.